Neurological Sciences

, Volume 32, Issue 4, pp 559–569 | Cite as

The concept of FDG-PET endophenotype in Alzheimer’s disease

  • Emmanuel H. During
  • R. S. Osorio
  • F. M. Elahi
  • L. Mosconi
  • M. J. de Leon
Review Article

Abstract

Often viewed as a potential tool for preclinical diagnosis in early asymptomatic stages of Alzheimer’s disease (AD), the term “endophenotype” has acquired a recent popularity in the field. In this review, we analyze the construct of endophenotype—originally designed to discover genes, and examine the literature on potential endophenotypes for the late-onset form of AD (LOAD). We focus on the [18F]-fluoro-2-deoxyglucose (FDG) PET technique, which shows a characteristic pattern of hypometabolism in AD-related regions in asymptomatic carriers of the ApoE E4 allele and in children of AD mothers. We discuss the pathophysiological significance and the positive predictive accuracy of an FDG-endophenotype for LOAD in asymptomatic subjects, and discuss several applications of this endophenotype in the identification of both promoting and protective factors. Finally, we suggest that the term “endophenotype” should be reserved to the study of risk factors, and not to the preclinical diagnosis of LOAD.

Keywords

Alzheimer’s disease FDG-PET Endophenotype Preclinical Diagnosis Genetics 

References

  1. 1.
    Brookmeyer R et al (2007) Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement 3(3):186–191PubMedCrossRefGoogle Scholar
  2. 2.
    Ohm TG et al (1995) Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer’s disease-related neurofibrillary changes. Neuroscience 64(1):209–217PubMedCrossRefGoogle Scholar
  3. 3.
    Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82(4):239–259PubMedCrossRefGoogle Scholar
  4. 4.
    Larson EB et al (2004) Survival after initial diagnosis of Alzheimer disease. Ann Intern Med 140(7):501–509PubMedGoogle Scholar
  5. 5.
    Mölsä PK, Marttila RJ, Rinne UK (1986) Survival and cause of death in Alzheimer’s disease and multi-infarct dementia. Acta Neurol Scand 74(2):103–107PubMedCrossRefGoogle Scholar
  6. 6.
    Reiman EM (2007) Linking brain imaging and genomics in the study of Alzheimer’s disease and aging. Ann N Y Acad Sci 1097:94–113PubMedCrossRefGoogle Scholar
  7. 7.
    Bearden CE, Freimer NB (2006) Endophenotypes for psychiatric disorders: ready for primetime? Trends Genet 22(6):306–313PubMedCrossRefGoogle Scholar
  8. 8.
    Leboyer M et al (1998) Psychiatric genetics: search for phenotypes. Trends Neurosci 21(3):102–105PubMedCrossRefGoogle Scholar
  9. 9.
    Sunderland T et al (2006) Biomarkers in the diagnosis of Alzheimer’s disease: are we ready? J Geriatr Psychiatry Neurol 19(3):172–179PubMedCrossRefGoogle Scholar
  10. 10.
    John B, Lewis KR (1966) Chromosome variability and geographic distribution in insects. Science 152(3723):711–721PubMedCrossRefGoogle Scholar
  11. 11.
    Gottesman II, Shields J (1973) Genetic theorizing and schizophrenia. Br J Psychiatry 122(566):15–30PubMedCrossRefGoogle Scholar
  12. 12.
    Gottesman II, Gould TD (2003) The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 160(4):636–645PubMedCrossRefGoogle Scholar
  13. 13.
    Hasler G et al (2006) Toward constructing an endophenotype strategy for bipolar disorders. Biol Psychiatry 60(2):93–105PubMedCrossRefGoogle Scholar
  14. 14.
    Cadenhead KS et al (2000) Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: evidence of inhibitory deficits. Am J Psychiatry 157(10):1660–1668PubMedCrossRefGoogle Scholar
  15. 15.
    Braff D, Geyer M, Swerdlow N (2001) Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology 156:234–258PubMedCrossRefGoogle Scholar
  16. 16.
    Braff D, Freedman R (2002) Endophenotypes in studies of the genetics of schizophrenia. In: Davis K et al (eds) Neuropsychopharamcology: the fifth generation of progress, 5th edn. Lippincott Williams and Wilkins, Philadelphia, pp 703–716Google Scholar
  17. 17.
    Diefendorf A, Dodge R (1908) An experimental study of the ocular reactions of the insane from photographic records. Brain 31:451–489CrossRefGoogle Scholar
  18. 18.
    Lee K, Williams L (2000) Eye movement dysfunction as a biological marker of risk for schizophrenia. Aust N Z J 34(Suppl):91–100Google Scholar
  19. 19.
    Freedman R et al (1997) Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci USA 94:587–592PubMedCrossRefGoogle Scholar
  20. 20.
    Arolt V et al (1996) Eye tracking dysfunction is a putative phenotypic susceptibility marker of schizophrenia and maps to a locus on chromosome 6p in families with multiple occurrence of the disease. Am J Med Genet 67(6):564–579PubMedCrossRefGoogle Scholar
  21. 21.
    Gasperoni TL et al (2003) Genetic linkage and association between chromosome 1q and working memory function in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 116B(1):8–16PubMedCrossRefGoogle Scholar
  22. 22.
    Callicott JH et al (2003) Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively intact siblings of patients with schizophrenia. Am J Psychiatry 160(4):709–719PubMedCrossRefGoogle Scholar
  23. 23.
    Corder EH et al (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261(5123):921–923PubMedCrossRefGoogle Scholar
  24. 24.
    Poirier J et al (1993) Apolipoprotein E polymorphism and Alzheimer’s disease. Lancet 342(8873):697–699PubMedCrossRefGoogle Scholar
  25. 25.
    Cupples LA et al (2004) Estimating risk curves for first-degree relatives of patients with Alzheimer’s disease: the REVEAL study. Genet Med. 6(4):192–196PubMedCrossRefGoogle Scholar
  26. 26.
    Bloss CS et al (2008) Decreased cognition in children with risk factors for Alzheimer’s disease. Biol Psychiatry 64(10):904–906PubMedCrossRefGoogle Scholar
  27. 27.
    Ponomareva NV, Korovaitseva GI, Rogaev EI (2008) EEG alterations in non-demented individuals related to apolipoprotein E genotype and to risk of Alzheimer disease. Neurobiol Aging 29(6):819–827PubMedCrossRefGoogle Scholar
  28. 28.
    Younkin SG et al (1998) Genetic elevation of plasma amyloid ß protein in typical late onset Alzheimer’s disease. Abstr Soc Neurosci 24:263Google Scholar
  29. 29.
    Sunderland T et al (2004) Cerebrospinal fluid beta-amyloid1–42 and tau in control subjects at risk for Alzheimer’s disease: the effect of APOE epsilon4 allele. Biol Psychiatry 56(9):670–676PubMedCrossRefGoogle Scholar
  30. 30.
    Honea RA et al (2010) Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease. Neurology 74(2):113–120PubMedCrossRefGoogle Scholar
  31. 31.
    Klunk WE et al (2004) Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 55(3):306–319PubMedCrossRefGoogle Scholar
  32. 32.
    Reiman EM et al (2009) Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer’s disease. Proc Natl Acad Sci USA 106(16):6820–6825PubMedCrossRefGoogle Scholar
  33. 33.
    Mosconi L et al (2010) Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer’s. Proc Natl Acad Sci USA 107(13):5949–5954PubMedCrossRefGoogle Scholar
  34. 34.
    de Leon MJ et al (1983) Computed tomography and positron emission transaxial tomography evaluations of normal aging and Alzheimer’s disease. J Cereb Blood Flow Metab 3(3):391–394PubMedCrossRefGoogle Scholar
  35. 35.
    Magistretti P et al (1999) Energy on demand. Science 283(5401):496–497PubMedCrossRefGoogle Scholar
  36. 36.
    Rocher AB et al (2003) Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons. Neuroimage 20(3):1894–1898PubMedCrossRefGoogle Scholar
  37. 37.
    de Leon MJ et al (2001) Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 98(19):10966–10971PubMedCrossRefGoogle Scholar
  38. 38.
    De Santi S et al (2001) Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 22(4):529–539PubMedCrossRefGoogle Scholar
  39. 39.
    Mosconi L et al (2008) Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging 29(5):676–692PubMedCrossRefGoogle Scholar
  40. 40.
    Herholz K et al (2002) Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 17(1):302–316PubMedCrossRefGoogle Scholar
  41. 41.
    Alexander GE et al (2002) Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer’s disease treatment studies. Am J Psychiatry 159(5):738–745PubMedCrossRefGoogle Scholar
  42. 42.
    Mosconi L (2005) Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD. Eur J Nucl Med. Mol Imaging 32(4):486–510PubMedCrossRefGoogle Scholar
  43. 43.
    Li Y et al (2008) Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer’s disease. Eur J Nucl Med Mol Imaging 35(12):2169–2181PubMedCrossRefGoogle Scholar
  44. 44.
    Reisberg B et al (2008) Mild cognitive impairment (MCI): a historical perspective. Int Psychogeriatr 20(1):18–31PubMedGoogle Scholar
  45. 45.
    Gauthier S et al (2006) Mild cognitive impairment. Lancet 367(9518):1262–1270PubMedCrossRefGoogle Scholar
  46. 46.
    Nestor PJ et al (2003) Limbic hypometabolism in Alzheimer’s disease and mild cognitive impairment. Ann Neurol 54(3):343–351PubMedCrossRefGoogle Scholar
  47. 47.
    Mosconi L et al (2005) Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology 64(11):1860–1867PubMedCrossRefGoogle Scholar
  48. 48.
    Mosconi L et al (2006) Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer’s disease using FDG-PET. Eur J Nucl Med Mol Imaging 33(2):210–221PubMedCrossRefGoogle Scholar
  49. 49.
    Minoshima S et al (1997) Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol 42(1):85–94PubMedCrossRefGoogle Scholar
  50. 50.
    Drzezga A et al (2003) Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer’s disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 30(8):1104–1113PubMedCrossRefGoogle Scholar
  51. 51.
    Mosconi L et al (2004) MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 63(12):2332–2340PubMedGoogle Scholar
  52. 52.
    Drzezga A et al (2005) Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med 46(10):1625–1632PubMedGoogle Scholar
  53. 53.
    Chételat G et al (2003) Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer’s disease? Neurology 60(8):1374–1377PubMedGoogle Scholar
  54. 54.
    Reiman EM, Langbaum JBS, Tariot PN (2010) Alzheimer’s prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark Med 4(1):3–14PubMedCrossRefGoogle Scholar
  55. 55.
    Small GW (2006) Diagnostic issues in dementia: neuroimaging as a surrogate marker of disease. J Geriatr Psychiatry Neurol 19(3):180–185PubMedCrossRefGoogle Scholar
  56. 56.
    Reiman EM et al (1996) Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 334(12):752–758PubMedCrossRefGoogle Scholar
  57. 57.
    Small GW et al (2000) Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease. Proc Natl Acad Sci USA 97(11):6037–6042PubMedCrossRefGoogle Scholar
  58. 58.
    Reiman EM et al (2001) Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer’s disease. Proc Natl Acad Sci USA 98(6):3334–3339PubMedCrossRefGoogle Scholar
  59. 59.
    Reiman EM et al (2004) Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementia. Proc Natl Acad Sci USA 101(1):284–289PubMedCrossRefGoogle Scholar
  60. 60.
    Reiman EM et al (2005) Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci USA 102(23):8299–8302PubMedCrossRefGoogle Scholar
  61. 61.
    Rimajova M et al (2008) Fluoro-2-deoxy-d-glucose (FDG)-PET in APOEepsilon4 carriers in the Australian population. J Alzheimers Dis 13(2):137–146PubMedGoogle Scholar
  62. 62.
    Mosconi L et al (2008) Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol Psychiatry 63(6):609–618PubMedCrossRefGoogle Scholar
  63. 63.
    Small GW et al (1995) Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 273(12):942–947PubMedCrossRefGoogle Scholar
  64. 64.
    Mosconi L et al (2007) Maternal family history of Alzheimer’s disease predisposes to reduced brain glucose metabolism. Proc Natl Acad Sci USA 104(48):9067–9072CrossRefGoogle Scholar
  65. 65.
    Mosconi L et al (2009) Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease. Neurology 72(6):513–520PubMedCrossRefGoogle Scholar
  66. 66.
    Gatz M et al (2006) Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 63(2):168–174PubMedCrossRefGoogle Scholar
  67. 67.
    Raber J, Huang Y, Ashford JW (2004) ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging 25(5):641–650PubMedCrossRefGoogle Scholar
  68. 68.
    Saunders AM et al (1993) Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 43(8):1467–1472PubMedGoogle Scholar
  69. 69.
    Poirier J (1994) Apolipoprotein E in animal models of CNS injury and in Alzheimer’s disease. Trends Neurosci 17(12):525–530PubMedCrossRefGoogle Scholar
  70. 70.
    Holtzman DM et al (2000) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA 97(6):2892–2897PubMedCrossRefGoogle Scholar
  71. 71.
    Bell RD et al (2007) Transport pathways for clearance of human Alzheimer’s amyloid betapeptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 27:909–918PubMedGoogle Scholar
  72. 72.
    Xu G et al (2008) The influence of parental history of Alzheimer’s disease and apolipoprotein E 4 on the BOLD signal during recognition memory. Brain 132(2):383–391PubMedCrossRefGoogle Scholar
  73. 73.
    Bookheimer SY et al (2000) Patterns of brain activation in people at risk for Alzheimer’s disease. N Engl J Med 343(7):450–456PubMedCrossRefGoogle Scholar
  74. 74.
    Prince JA et al (2004) APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. Neurology 62(11):2116–2118PubMedGoogle Scholar
  75. 75.
    Morris JC et al (2010) APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67(1):122–131PubMedCrossRefGoogle Scholar
  76. 76.
    Mosconi L et al (2010) Maternal transmission of Alzheimer’s disease: prodromal metabolic phenotype and the search for genes. Hum Genomics 4(3):170–193PubMedGoogle Scholar
  77. 77.
    Edland SD et al (1996) Increased risk of dementia in mothers of Alzheimer’s disease cases: evidence for maternal inheritance. Neurology 47(1):254–256PubMedGoogle Scholar
  78. 78.
    Gómez-Tortosa E et al (2007) Variability of age at onset in siblings with familial Alzheimer disease. Arch Neurol 64(12):1743–1748PubMedCrossRefGoogle Scholar
  79. 79.
    Parker WD, Filley CM, Parks JK (1990) Cytochrome oxidase deficiency in Alzheimer’s disease. Neurology 40(8):1302–1303PubMedGoogle Scholar
  80. 80.
    Swerdlow RH, Burns JM, Khan SM (2010) The Alzheimer’s disease mitochondrial cascade hypothesis. J Alzheimers Dis 20(Suppl 2):S265–S279PubMedGoogle Scholar
  81. 81.
    Cardoso SM et al (2004) Mitochondria dysfunction of Alzheimer’s disease cybrids enhances Abeta toxicity. J Neurochem 89(6):1417–1426PubMedCrossRefGoogle Scholar
  82. 82.
    Chen Y, Bidwell LC, Norton D (2006) Trait vs. state markers for schizophrenia: identification and characterization through visual processes. Curr Psychiatry Rev 2(4):431–438PubMedCrossRefGoogle Scholar
  83. 83.
    Jagust W et al (2006) Brain imaging evidence of preclinical Alzheimer’s disease in normal aging. Ann Neurol 59(4):673–681PubMedCrossRefGoogle Scholar
  84. 84.
    Mosconi L et al (2009) FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s disease. Eur J Nucl Med Mol Imaging 36(5):811–822PubMedCrossRefGoogle Scholar
  85. 85.
    Gómez-Isla T et al (1996) Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer’s disease. J Neurosci 16(14):4491–4500PubMedGoogle Scholar
  86. 86.
    Fjell AM et al (2008) Morphometric changes in the episodic memory network and tau pathologic features correlate with memory performance in patients with mild cognitive impairment. Am J Neuroradiol 29(6):1183–1189PubMedCrossRefGoogle Scholar
  87. 87.
    Jack CR et al (2009) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain 132(Pt 5):1355–1365PubMedCrossRefGoogle Scholar
  88. 88.
    Buckner RL et al (2009) Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer’s disease. J Neurosci 29(6):1860–1873PubMedCrossRefGoogle Scholar
  89. 89.
    Raichle ME et al (2001) A default mode of brain function. Proc Natl Acad Sci USA 98(2):676–682PubMedCrossRefGoogle Scholar
  90. 90.
    Sleegers K et al (2010) The pursuit of susceptibility genes for Alzheimer’s disease: progress and prospects. Trends Genet 26(2):84–93PubMedCrossRefGoogle Scholar
  91. 91.
    Glahn DC, Thompson PM, Blangero J (2007) Neuroimaging endophenotypes: strategies for finding genes influencing brain structure and function. Hum Brain Mapp 28:488–501PubMedCrossRefGoogle Scholar
  92. 92.
    Jun G. et al. (2010) Meta-analysis Confirms CR1, CLU, and PICALM as Alzheimer Disease Risk Loci and Reveals Interactions With APOE Genotypes. Arch Neurol (ahead of print)Google Scholar
  93. 93.
    Saykin AJ et al (2010) Alzheimer’s disease neuroimaging initiative biomarkers as quantitative phenotypes: genetics core aims, progress, and plans. Alzheimer’s Dement 6(3):265–273CrossRefGoogle Scholar
  94. 94.
    Corder EH et al (1994) Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 7(2):180–184PubMedCrossRefGoogle Scholar
  95. 95.
    West HL, Rebeck GW, Hyman BT (1994) Frequency of the apolipoprotein E [epsilon] 2 allele is diminished in sporadic Alzheimer disease. Neurosci Lett 175(1–2):46–48PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Emmanuel H. During
    • 1
  • R. S. Osorio
    • 1
    • 2
  • F. M. Elahi
    • 3
    • 4
  • L. Mosconi
    • 1
  • M. J. de Leon
    • 1
    • 5
  1. 1.Center for Brain Health, Silberstein Alzheimer’s InstituteCenter of Excellence on Brain Aging at NYU Langone Medical Center, NYU School of MedicineNew YorkUSA
  2. 2.Alzheimer’s Disease Research UnitCIEN Foundation-Carlos III Institute of Health, Alzheimer Center ReinaMadridSpain
  3. 3.Department of NeurologyUniversity of California, Los Angeles (UCLA)Los AngelesUSA
  4. 4.Wellcome Trust Centre for Human GeneticsUniversity of OxfordOxfordUK
  5. 5.Nathan Kline InstituteOrangeburgUSA

Personalised recommendations